The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.
In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 Expressors
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.
NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...
The collaboration will focus on identifying protein biomarkers associated with immunotherapy response across cancer types.
As part of the deal, the companies said they will work together to advance gene therapies for diseases with high unmet medical need.
The firm will evaluate the engineered cell therapy in patients with melanoma, and non-small cell lung, head and neck, colorectal, pancreatic, and cervical cancer.
The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.
The company said it expects this restructuring plan to result in its quarterly cash flow breaking even by the second half of next year.
During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.
At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback